Asia PR News

SYDNEY, Dec. 29 /AsiaNet/ –

AsiaNet Daily Summary - Press Releases for Thursday December
29

SYDNEY, Dec. 29 /AsiaNet/ –

DRUG APPROVAL…
BASEL, Switzerland - Novartis announced today the US
regulatory approval of Femara (letrozole) in a new indication
as a treatment for use after surgery in postmenopausal women
with hormone-sensitive early breast cancer (adjuvant
setting).
http://www.novartis.com
http://www.femarainfo.com
http://www.novartisoncology.com

DRUG FINDINGS…
BERNE - According to newly published data, postmenopausal
women with hormone-sensitive early breast cancer receiving
letrozole following surgery (adjuvant use) have a significantly
greater chance of avoiding a recurrence than do women receiving
tamoxifen.
http://www.ibcsg.org

BIO SUMMIT…
WASHINGTON - The Biotechnology Industry Organization (BIO),
the U.S. Embassy in Tokyo, and the state of Hawaii will host a
Japanese Bio Mission at the Pacific Rim Summit on Industrial
Biotechnology and Bioenergy in Honolulu Jan. 11-13, 2006.
http://www.bio.org

FANNIE MAE…
WASHINGTON, D.C. - Fannie Mae will redeem the principal
amount of 1 securities issue amounting to a total of US$25
million on January 9, 2006, at a redemption price equal to 100
per cent of the principal amount redeemed plus accrued
interest.
http://www.fanniemae.com

FDA APPROVAL…
SUMMIT, N.J. - Celgene Corporation announced that the U.S.
Food and Drug Administration granted approval of REVLIMID
(lenalidomide) which is indicated for the treatment of patients
with transfusion-dependent anemia due to low- or
intermediate-1-risk myelodysplastic syndromes (MDS) associated
with a deletion 5q cytogenetic abnormality with or without
additional cytogenetic abnormalities.
http://www.celgene.com
http://www.REVLIMID.com

AsiaNet is a consortium of leading news agencies
distributing unedited, translated news releases for worldwide
clients. Visit www.asianetnews.net for full-text versions.